Your browser doesn't support javascript.
loading
Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.
Van Assche, G; Baert, F; Vermeire, S.
Affiliation
  • Van Assche G; Division of Gastroenterology, University Hospitals Leuven, Belgium. gert.vanassche@uzleuven.be
Aliment Pharmacol Ther ; 35(7): 848; discussion 849, 2012 Apr.
Article in En | MEDLINE | ID: mdl-22404407
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Antibodies, Monoclonal, Humanized / Anti-Inflammatory Agents Limits: Female / Humans / Male Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2012 Document type: Article Affiliation country: Belgium Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Antibodies, Monoclonal, Humanized / Anti-Inflammatory Agents Limits: Female / Humans / Male Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2012 Document type: Article Affiliation country: Belgium Country of publication: United kingdom